Tina K Thethi1, Muhammad A Bajwa2, Husam Ghanim3, Chanhee Jo4, Monica Weir4, Allison B Goldfine5, Guillermo Umpierrez6, Cyrus Desouza7, Paresh Dandona3, Ying Fang-Hollingsworth4, Vasudevan Raghavan4, Vivian A Fonseca8. 1. Tulane University Health Sciences Center, New Orleans, LA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA. Electronic address: tthethi@tulane.edu. 2. Joslin Diabetes Center, Boston, MA. 3. Diabetes-Endocrinology Center of Western NY, Buffalo, NY. 4. Scott & White Clinic, Temple, TX. 5. Joslin Diabetes Center, Boston, MA; Harvard Medical School, Boston, MA. 6. Emory University, Atlanta, GA. 7. University of Nebraska, Omaha, NB. 8. Tulane University Health Sciences Center, New Orleans, LA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA.
Abstract
AIMS: Patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) have impaired endothelial function. Vitamin D and its analogs may play a role in regulation of endothelial function and inflammation. We studied effects of paricalcitol compared to placebo on endothelial function and markers of inflammation and oxidative stress in patients with T2DM and CKD. METHODS: A double blind, randomized, placebo-controlled trial was conducted in 60 patients with T2DM and stage 3 or 4 CKD. Paricalcitol 1 mcg or placebo was administered orally once daily for three months. Brachial artery flow mediated dilatation (FMD), nitroglycerine mediated dilation (NMD), and plasma concentrations of inflammatory cytokines, tumor necrosis factor -α and interleukin-6, highly-sensitive C-reactive protein; endothelial surface proteins, intercellular adhesion molecule -1 and monocyte chemo attractant protein-1, and plasma glucose, insulin, free fatty acids, and urinary isoprostane were measured at baseline and end of three months. RESULTS:27 patients in theparicalcitol group and 28 patients in the control group completed the study, though analysis of FMD at both time points was possible in 23 patients in each group. There was no significant difference in the change in FMD, NMD or the biomarkers examined after paricalcitol or placebo treatment. CONCLUSIONS: Treatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress. The lack of significance may be due to the fact that the study patients had advanced CKD and that effects of paricalcitol are not additive to the effects of glycemic, lipid and anti-hypertensive therapies. Published by Elsevier Inc.
RCT Entities:
AIMS: Patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) have impaired endothelial function. Vitamin D and its analogs may play a role in regulation of endothelial function and inflammation. We studied effects of paricalcitol compared to placebo on endothelial function and markers of inflammation and oxidative stress in patients with T2DM and CKD. METHODS: A double blind, randomized, placebo-controlled trial was conducted in 60 patients with T2DM and stage 3 or 4 CKD. Paricalcitol 1 mcg or placebo was administered orally once daily for three months. Brachial artery flow mediated dilatation (FMD), nitroglycerine mediated dilation (NMD), and plasma concentrations of inflammatory cytokines, tumor necrosis factor -α and interleukin-6, highly-sensitive C-reactive protein; endothelial surface proteins, intercellular adhesion molecule -1 and monocyte chemo attractant protein-1, and plasma glucose, insulin, free fatty acids, and urinary isoprostane were measured at baseline and end of three months. RESULTS: 27 patients in the paricalcitol group and 28 patients in the control group completed the study, though analysis of FMD at both time points was possible in 23 patients in each group. There was no significant difference in the change in FMD, NMD or the biomarkers examined after paricalcitol or placebo treatment. CONCLUSIONS: Treatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress. The lack of significance may be due to the fact that the study patients had advanced CKD and that effects of paricalcitol are not additive to the effects of glycemic, lipid and anti-hypertensive therapies. Published by Elsevier Inc.
Authors: Maria-Dolores Sanchez-Niño; Milica Bozic; Elizabeth Córdoba-Lanús; Petya Valcheva; Olga Gracia; Merce Ibarz; Elvira Fernandez; Juan F Navarro-Gonzalez; Alberto Ortiz; Jose Manuel Valdivielso Journal: Am J Physiol Renal Physiol Date: 2011-12-14
Authors: Seth I Sokol; Vankeepuram Srinivas; Jill P Crandall; Mimi Kim; George Tellides; Amir H Lebastchi; Amir Lebastchi; Yiting Yu; Alok K Gupta; Michael H Alderman Journal: Vasc Med Date: 2012-12 Impact factor: 3.239
Authors: Juan F Navarro-González; Javier Donate-Correa; María L Méndez; Mercedes Muros de Fuentes; Javier García-Pérez; Carmen Mora-Fernández Journal: J Clin Pharmacol Date: 2013-02-20 Impact factor: 3.126
Authors: Nihil Chitalia; Tuan Ismail; Laura Tooth; Frances Boa; Geeta Hampson; David Goldsmith; Juan Carlos Kaski; Debasish Banerjee Journal: PLoS One Date: 2014-03-19 Impact factor: 3.240
Authors: Jessica Kendrick; Emily Andrews; Zhiying You; Kerrie Moreau; Kristen L Nowak; Heather Farmer-Bailey; Douglas R Seals; Michel Chonchol Journal: Clin J Am Soc Nephrol Date: 2017-08-07 Impact factor: 8.237
Authors: José Pedraza-Chaverri; Laura G Sánchez-Lozada; Horacio Osorio-Alonso; Edilia Tapia; Alexandra Scholze Journal: Oxid Med Cell Longev Date: 2016-06-27 Impact factor: 6.543
Authors: Ladan Mansouri; Kristina Lundwall; Ali Moshfegh; Stefan H Jacobson; Joachim Lundahl; Jonas Spaak Journal: BMC Nephrol Date: 2017-05-16 Impact factor: 2.388